Stocks
GT Biopharma, Inc.GTBP
NASDAQHealthcareBiotechnology$5.52
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing bispecific natural killer cell engagers for oncology and autoimmune indications. Its lead candidates target CD16A and tumor-associated antigens, with early-phase trials in acute myeloid leukemia and other hematologic malignancies. Investors track GTBP for its novel NK cell-based platform and potential in solid tumors.
52W Range: $4.91-$28.75
Congressional Interest in GT Biopharma, Inc. (GTBP)
No congressional trades have been disclosed for GT Biopharma, Inc. (GTBP) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading GTBP?
No congressional trades found for this stock.